Macedonian drug maker Alkaloid posted a consolidated net profit of 666.5 million denars (12.3 million/10.8 million euro) for 2015, up from 618.5 million denars in 2014, the company said in a bourse filing.
Sales revenue rose to 7.9 billion denars last year from 7.4 billion denars in 2014, Alkaloid said in its consolidated income statement posted on its website on Monday.
Operating profit increased to 780.9 million denars in 2015 from 775.6 million in 2014.
Total investments in fixed assets amounted to 987 million denars last year.
Skopje-based Alkaloid is part of both the Macedonian bourse blue-chip MBI index and the SEELinX benchmark of the recently launched SEE Link platform for trading of securities listed on equity markets in Bulgaria, Macedonia and Croatia.
The company has three subsidiaries in Macedonia, as well as 14 subsidiaries and four representative offices abroad - in Serbia, Montenegro, Kosovo, Albania, Bosnia and Herzegovina, Croatia, Slovenia, Switzerland, Bulgaria, Turkey, Ukraine, Russia, and the US.
